Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

MXCT

Maxcyte (MXCT)

Maxcyte Inc
일자:
정렬 기준:
 검색 관련기사 보기:LSE:MXCT
일자시간출처헤드라인심볼기업
2024/05/0817:46Alliance NewsAlliance NewsMaxCyte shares rise amid double-digit revenue increaseLSE:MXCTMaxcyte Inc
2024/05/0815:05RNS Regulatory NewsMaxCyte, Inc. Filing of Form 10-QLSE:MXCTMaxcyte Inc
2024/05/0815:00RNS Regulatory NewsMaxCyte, Inc. First Quarter ResultsLSE:MXCTMaxcyte Inc
2024/05/0315:00RNS Regulatory NewsMaxCyte, Inc. Notice of AGMLSE:MXCTMaxcyte Inc
2024/05/0201:04RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
2024/04/1021:05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
2024/04/0315:00RNS Regulatory NewsMaxCyte, Inc. Total Voting Rights and Block Listing ReturnLSE:MXCTMaxcyte Inc
2024/04/0223:19Alliance NewsAlliance NewsTRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmoutLSE:MXCTMaxcyte Inc
2024/04/0221:05RNS Regulatory NewsMaxCyte, Inc. Signing of Strategic Platform LicenseLSE:MXCTMaxcyte Inc
2024/04/0215:00RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
2024/03/2019:16RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
2024/03/2019:05RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
2024/03/1320:54Alliance NewsAlliance NewsIN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%LSE:MXCTMaxcyte Inc
2024/03/1316:05RNS Regulatory NewsMaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023LSE:MXCTMaxcyte Inc
2024/03/1316:00RNS Regulatory NewsMaxCyte, Inc. Reports Q4 & FY 2023 Financial ResultsLSE:MXCTMaxcyte Inc
2024/03/1305:05UK RegulatoryMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceLSE:MXCTMaxcyte Inc
2024/03/0617:58RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
2024/03/0605:43Alliance NewsAlliance NewsEARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profitLSE:MXCTMaxcyte Inc
2024/03/0516:00RNS Regulatory NewsMaxCyte, Inc. Preliminary FY Results & 2024 GuidanceLSE:MXCTMaxcyte Inc
2024/03/0506:05UK RegulatoryMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsLSE:MXCTMaxcyte Inc
2024/03/0202:57RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
2024/02/2918:21RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
2024/02/2616:00RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
2024/02/0922:05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
2024/02/0922:05UK RegulatoryMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesLSE:MXCTMaxcyte Inc
2024/02/0118:24RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
2024/01/3116:00RNS Regulatory NewsMaxCyte, Inc. Director/PDMR ShareholdingLSE:MXCTMaxcyte Inc
2024/01/3023:29RNS Regulatory NewsMaxCyte, Inc. Holding(s) in CompanyLSE:MXCTMaxcyte Inc
2024/01/3022:58Alliance NewsAlliance NewsIN BRIEF: MaxCyte signs licencing deal with cell therapy company WugenLSE:MXCTMaxcyte Inc
2024/01/3022:05UK RegulatoryMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersLSE:MXCTMaxcyte Inc
 검색 관련기사 보기:LSE:MXCT

최근 히스토리

Delayed Upgrade Clock